Candel Therapeutics (CADL) Receivables (2020 - 2021)
Candel Therapeutics' (CADL) quarterly Receivables came in at $1.1 million in Q4 2021, up 72.44% year-on-year from $624000.0 in Q4 2020, and up 463.35% quarter-over-quarter from $191000.0 in Q1 2021.
Candel Therapeutics (CADL) Receivables (2020 - 2021) Analysis & Trends
Candel Therapeutics has disclosed Receivables across 2 years of filings, most recently posting $1.1 million for Q4 2021.
- Receivables for Q4 2021 came in at $1.1 million, up 72.44% year-over-year; the trailing twelve-month figure through Dec 2021 was $1.1 million (up 72.44% YoY), and the FY2021 annual result was $1.1 million, up 72.44% from the prior year.
- Receivables came in at $1.1 million for Q4 2021 at Candel Therapeutics, up from $191000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $1.1 million in Q4 2021 to a low of $191000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Candel Therapeutics | 440.62 Mn | 440.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.08 Mn |
| Mar 31, 2021 | 191,000.00 |
| Dec 31, 2020 | 624,000.00 |